One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study

OBJECTIVE: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS: Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Goadsby, Peter J., Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H., Zhang, Feng, Wright, Ian K., Chou, Denise E., Klatt, Jan, Picard, Hernan, Lenz, Robert A., Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455346/
https://www.ncbi.nlm.nih.gov/pubmed/32636324
http://dx.doi.org/10.1212/WNL.0000000000010019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455346/
https://www.ncbi.nlm.nih.gov/pubmed/32636324
http://dx.doi.org/10.1212/WNL.0000000000010019

Ejemplares similares